Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Posts Revenue Rise Amidst Losses

SAN FRANCISCO, Aug. 7 - Bruker Daltonics today reported an increase in second quarter revenue against the backdrop of net losses.


For the three months ended June 30, Bruker reported total revenues of $28 million compared with $22.3 million for the same period one year ago.


Net loss for the quarter was $4.2 million, or $.08 per share, compared to a gain of $833,000, or $.02 per share, for the year-ago period.


In the second quarter, Bruker said it took a $1.5 million pretax restructuring charge, mostly for workforce reduction and cost savings programs, and wrote down its investment in a proteomics company by $4.4 million pretax.


In July, Bruker announced layoffs of approximately 10 percent of its workforce due to "on-going uncertain economic conditions," according to the company.


R&D spending rose to approximately $5.1 million from $4.6 million for the second quarter in 2001


The company said it had roughly $54.8 million in cash and short-term investments as of June 30.


Click here for more information.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.